ProPhase Labs (NASDAQ:PRPH) Stock Price Crosses Above 200-Day Moving Average of $4.77

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.77 and traded as high as $6.55. ProPhase Labs shares last traded at $6.47, with a volume of 16,000 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Trading Up 3.4 %

The company has a market capitalization of $116.78 million, a PE ratio of -11.76 and a beta of -0.34. The stock has a fifty day moving average of $5.09 and a two-hundred day moving average of $4.77. The company has a current ratio of 3.04, a quick ratio of 2.73 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PRPH. Tower Research Capital LLC TRC purchased a new position in ProPhase Labs in the 2nd quarter worth $42,000. Royal Bank of Canada lifted its stake in shares of ProPhase Labs by 2,166.7% in the 2nd quarter. Royal Bank of Canada now owns 10,880 shares of the company’s stock valued at $79,000 after acquiring an additional 10,400 shares during the last quarter. Jane Street Group LLC purchased a new stake in ProPhase Labs during the 4th quarter valued at about $118,000. Goldman Sachs Group Inc. bought a new position in ProPhase Labs during the 2nd quarter worth approximately $164,000. Finally, Morgan Stanley lifted its position in ProPhase Labs by 50.8% in the fourth quarter. Morgan Stanley now owns 14,683 shares of the company’s stock valued at $141,000 after purchasing an additional 4,945 shares during the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.